Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0O9DK
|
||||
| Former ID |
DIB010497
|
||||
| Drug Name |
PF-05280586
|
||||
| Indication | Cluster headache [ICD10:G44.0] | Phase 3 | [1] | ||
| Company |
Pfizer
|
||||
| Target and Pathway | |||||
| Target(s) | B-lymphocyte antigen CD20 | Target Info | Antagonist | [2] | |
| KEGG Pathway | Hematopoietic cell lineage | ||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT02213263) A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06). U.S. National Institutes of Health. | ||||
| REF 2 | Comparative nonclinical assessments of the proposed biosimilar PF-05280586 and rituximab (MabThera?). Toxicol Pathol. 2014 Oct;42(7):1069-81. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.